{"id": "article-35631_0", "title": "Apixaban -- Continuing Education Activity", "content": "Apixaban is a novel oral anticoagulant approved by the US Food and Drug Administration (FDA) in 2012 for use in patients with nonvalvular atrial fibrillation to reduce the risk of stroke and blood clots.\u00a0Later, in 2014, apixaban gained approval for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), as well as for reducing the risk of blood clots (DVT and PE) in patients who have undergone knee or hip replacement surgery.\u00a0The drug is also approved for reducing the risk of recurrent DVT and PE after initial therapy.", "contents": "Apixaban -- Continuing Education Activity. Apixaban is a novel oral anticoagulant approved by the US Food and Drug Administration (FDA) in 2012 for use in patients with nonvalvular atrial fibrillation to reduce the risk of stroke and blood clots.\u00a0Later, in 2014, apixaban gained approval for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), as well as for reducing the risk of blood clots (DVT and PE) in patients who have undergone knee or hip replacement surgery.\u00a0The drug is also approved for reducing the risk of recurrent DVT and PE after initial therapy."}
{"id": "article-35631_1", "title": "Apixaban -- Continuing Education Activity", "content": "This activity outlines the indications, mechanism of action, safe administration, adverse effects, contraindications, monitoring, overdose management, and toxicity of apixaban, thereby providing clinicians with a robust understanding of apixaban for treating various conditions and facilitating informed decision-making. This activity emphasizes that premature apixaban discontinuation heightens thrombotic event risks, necessitating consideration of alternative anticoagulants.\u00a0By addressing these significant topics, this activity aims to enhance the proficiency and competence of healthcare professionals in managing apixaban therapy, thereby leading to improved patient outcomes.", "contents": "Apixaban -- Continuing Education Activity. This activity outlines the indications, mechanism of action, safe administration, adverse effects, contraindications, monitoring, overdose management, and toxicity of apixaban, thereby providing clinicians with a robust understanding of apixaban for treating various conditions and facilitating informed decision-making. This activity emphasizes that premature apixaban discontinuation heightens thrombotic event risks, necessitating consideration of alternative anticoagulants.\u00a0By addressing these significant topics, this activity aims to enhance the proficiency and competence of healthcare professionals in managing apixaban therapy, thereby leading to improved patient outcomes."}
{"id": "article-35631_2", "title": "Apixaban -- Continuing Education Activity", "content": "Objectives: Identify appropriate indications for apixaban therapy across various clinical scenarios, including nonvalvular atrial fibrillation, deep vein thrombosis, pulmonary embolism, and post-surgical prophylaxis. Implement evidence-based protocols for initiating, titrating, and monitoring apixaban therapy according to established guidelines and patient-specific factors. Assess patients regularly for bleeding risk factors, adherence to apixaban therapy, and signs of adverse effects, ensuring timely intervention and adjustment of treatment plans when necessary. Collaborate with other healthcare professionals to ensure seamless care coordination and continuity in apixaban therapy management based on patient characteristics, comorbidities, and preferences. Access free multiple choice questions on this topic.", "contents": "Apixaban -- Continuing Education Activity. Objectives: Identify appropriate indications for apixaban therapy across various clinical scenarios, including nonvalvular atrial fibrillation, deep vein thrombosis, pulmonary embolism, and post-surgical prophylaxis. Implement evidence-based protocols for initiating, titrating, and monitoring apixaban therapy according to established guidelines and patient-specific factors. Assess patients regularly for bleeding risk factors, adherence to apixaban therapy, and signs of adverse effects, ensuring timely intervention and adjustment of treatment plans when necessary. Collaborate with other healthcare professionals to ensure seamless care coordination and continuity in apixaban therapy management based on patient characteristics, comorbidities, and preferences. Access free multiple choice questions on this topic."}
{"id": "article-35631_3", "title": "Apixaban -- Indications", "content": "Apixaban is a novel oral anticoagulant (NOAC) approved by the US Food and Drug Administration (FDA) in 2012 for use in patients with nonvalvular atrial fibrillation to reduce the risk of stroke and blood clots, as mentioned below. [1] [2] This medication is approved for various other indications, as described below.", "contents": "Apixaban -- Indications. Apixaban is a novel oral anticoagulant (NOAC) approved by the US Food and Drug Administration (FDA) in 2012 for use in patients with nonvalvular atrial fibrillation to reduce the risk of stroke and blood clots, as mentioned below. [1] [2] This medication is approved for various other indications, as described below."}
{"id": "article-35631_4", "title": "Apixaban -- Indications -- FDA-Approved Indications", "content": "Apixaban is indicated for use in patients with nonvalvular atrial fibrillation to reduce the risk of stroke and systemic embolism. [3] According to the guidelines of the American Heart Association (AHA)/American College of Cardiology (ACC)/European Respiratory Society (ERS), apixaban is endorsed for use in nonvalvular atrial fibrillation (AF). [4]", "contents": "Apixaban -- Indications -- FDA-Approved Indications. Apixaban is indicated for use in patients with nonvalvular atrial fibrillation to reduce the risk of stroke and systemic embolism. [3] According to the guidelines of the American Heart Association (AHA)/American College of Cardiology (ACC)/European Respiratory Society (ERS), apixaban is endorsed for use in nonvalvular atrial fibrillation (AF). [4]"}
{"id": "article-35631_5", "title": "Apixaban -- Indications -- FDA-Approved Indications", "content": "Later, in 2014, apixaban gained approval for the treatment of deep\u00a0vein\u00a0thrombosis (DVT), [5] pulmonary embolism (PE), [6] and\u00a0prophylaxis in DVT, which may lead to PE, in patients who may have undergone knee or hip replacement surgery. [7] [8] The drug\u00a0is also approved for reducing the risk of recurrent DVT and PE after initial therapy. [9]", "contents": "Apixaban -- Indications -- FDA-Approved Indications. Later, in 2014, apixaban gained approval for the treatment of deep\u00a0vein\u00a0thrombosis (DVT), [5] pulmonary embolism (PE), [6] and\u00a0prophylaxis in DVT, which may lead to PE, in patients who may have undergone knee or hip replacement surgery. [7] [8] The drug\u00a0is also approved for reducing the risk of recurrent DVT and PE after initial therapy. [9]"}
{"id": "article-35631_6", "title": "Apixaban -- Indications -- Off-Label\u00a0Uses", "content": "Apixaban has been investigated in the context of COVID-19. Based on a thorough literature review, the current guidelines from the National Institutes of Health (NIH) state that there is insufficient evidence to recommend the use of a therapeutic dose of apixaban for prophylaxis against venous thromboembolism (VTE). The American Society of Hematology (ASH) recommends selecting a direct oral anticoagulant (DOAC) such as dabigatran, rivaroxaban, or apixaban for subacute heparin-induced thrombocytopenia type A (HIT A). This recommendation is supported by a moderate level of certainty in the evidence. ASH suggests DOACs as the preferred anticoagulant for clinically stable patients. However, in emergency settings, parenteral direct thrombin inhibitors are preferred. [10]", "contents": "Apixaban -- Indications -- Off-Label\u00a0Uses. Apixaban has been investigated in the context of COVID-19. Based on a thorough literature review, the current guidelines from the National Institutes of Health (NIH) state that there is insufficient evidence to recommend the use of a therapeutic dose of apixaban for prophylaxis against venous thromboembolism (VTE). The American Society of Hematology (ASH) recommends selecting a direct oral anticoagulant (DOAC) such as dabigatran, rivaroxaban, or apixaban for subacute heparin-induced thrombocytopenia type A (HIT A). This recommendation is supported by a moderate level of certainty in the evidence. ASH suggests DOACs as the preferred anticoagulant for clinically stable patients. However, in emergency settings, parenteral direct thrombin inhibitors are preferred. [10]"}
{"id": "article-35631_7", "title": "Apixaban -- Mechanism of Action", "content": "The clotting cascade of apixaban\u00a0encompasses a complex process comprising multiple factors operating in 3 distinct phases\u2014initiation, propagation, and fibrin formation. Initiation: This step is initiated when the vascular endothelium and the clotting factors are disturbed. Propagation: This step involves the production of large amounts of thrombin at the injury site. Fibrin formation: In this step, thrombin facilitates the conversion of fibrinogen into fibrin.", "contents": "Apixaban -- Mechanism of Action. The clotting cascade of apixaban\u00a0encompasses a complex process comprising multiple factors operating in 3 distinct phases\u2014initiation, propagation, and fibrin formation. Initiation: This step is initiated when the vascular endothelium and the clotting factors are disturbed. Propagation: This step involves the production of large amounts of thrombin at the injury site. Fibrin formation: In this step, thrombin facilitates the conversion of fibrinogen into fibrin."}
{"id": "article-35631_8", "title": "Apixaban -- Mechanism of Action", "content": "The coagulation proteins form the basic components of the coagulation system. They lead to complex reactions, converting plasma-soluble fibrinogen to insoluble fibrin strands. The clotting cascade has 2 main pathways\u2014the intrinsic and extrinsic. External trauma activates the extrinsic pathway and causes blood loss from the vascular system, and it is faster than the intrinsic pathway and involves factor VII. Trauma within the vascular system triggers platelet activation through exposure to endothelium, chemicals, or collagen, thereby potentially initiating the intrinsic pathway, which comprises factors XII, XI, IX, and VIII. Both pathways share a common ending where they activate factor X to Xa, which activates prothrombin (II) to thrombin (IIa), forming a stable clot.", "contents": "Apixaban -- Mechanism of Action. The coagulation proteins form the basic components of the coagulation system. They lead to complex reactions, converting plasma-soluble fibrinogen to insoluble fibrin strands. The clotting cascade has 2 main pathways\u2014the intrinsic and extrinsic. External trauma activates the extrinsic pathway and causes blood loss from the vascular system, and it is faster than the intrinsic pathway and involves factor VII. Trauma within the vascular system triggers platelet activation through exposure to endothelium, chemicals, or collagen, thereby potentially initiating the intrinsic pathway, which comprises factors XII, XI, IX, and VIII. Both pathways share a common ending where they activate factor X to Xa, which activates prothrombin (II) to thrombin (IIa), forming a stable clot."}
{"id": "article-35631_9", "title": "Apixaban -- Mechanism of Action", "content": "Apixaban is a highly selective direct factor Xa inhibitor that blocks the propagation phase of the coagulation cascade. This affects\u00a0both free and clot-bound factor Xa. Antithrombotic activity does not need antithrombin III. Factor Xa is a catalyst for converting prothrombin to thrombin, the final step in the coagulation cascade, leading to fibrin and clot formation. [11] Other direct factor Xa inhibitors include rivaroxaban and edoxaban. Apixaban exerts no effect on platelet aggregation.", "contents": "Apixaban -- Mechanism of Action. Apixaban is a highly selective direct factor Xa inhibitor that blocks the propagation phase of the coagulation cascade. This affects\u00a0both free and clot-bound factor Xa. Antithrombotic activity does not need antithrombin III. Factor Xa is a catalyst for converting prothrombin to thrombin, the final step in the coagulation cascade, leading to fibrin and clot formation. [11] Other direct factor Xa inhibitors include rivaroxaban and edoxaban. Apixaban exerts no effect on platelet aggregation."}
{"id": "article-35631_10", "title": "Apixaban -- Mechanism of Action -- Pharmacokinetics", "content": "Apixaban exhibits dose-linear pharmacokinetics up to a dose of 10 mg. [12]", "contents": "Apixaban -- Mechanism of Action -- Pharmacokinetics. Apixaban exhibits dose-linear pharmacokinetics up to a dose of 10 mg. [12]"}
{"id": "article-35631_11", "title": "Apixaban -- Mechanism of Action -- Pharmacokinetics", "content": "Absorption: The absolute bioavailability of apixaban is approximately 50% for doses up to 10 mg. Consumption of the drug with food does not alter its bioavailability. The peak plasma concentration of apixaban is typically achieved within 3 to 4 hours post-administration.", "contents": "Apixaban -- Mechanism of Action -- Pharmacokinetics. Absorption: The absolute bioavailability of apixaban is approximately 50% for doses up to 10 mg. Consumption of the drug with food does not alter its bioavailability. The peak plasma concentration of apixaban is typically achieved within 3 to 4 hours post-administration."}
{"id": "article-35631_12", "title": "Apixaban -- Mechanism of Action -- Pharmacokinetics", "content": "Distribution: Apixaban exhibits a plasma protein binding of approximately 87%, indicating high protein binding. In addition, the drug has a volume of distribution of approximately 21 L, suggesting moderate distribution into tissues. Metabolism: Apixaban is primarily metabolized via the enzyme CYP3A4. Approximately 25% of the orally administered dose of apixaban is eliminated in urine and feces as metabolites.", "contents": "Apixaban -- Mechanism of Action -- Pharmacokinetics. Distribution: Apixaban exhibits a plasma protein binding of approximately 87%, indicating high protein binding. In addition, the drug has a volume of distribution of approximately 21 L, suggesting moderate distribution into tissues. Metabolism: Apixaban is primarily metabolized via the enzyme CYP3A4. Approximately 25% of the orally administered dose of apixaban is eliminated in urine and feces as metabolites."}
{"id": "article-35631_13", "title": "Apixaban -- Mechanism of Action -- Pharmacokinetics", "content": "Elimination: Apixaban undergoes elimination via both urine and feces and has an apparent half-life of 12 hours following oral administration. Among the DOACs, apixaban exhibits 27% renal elimination, and dabigatran demonstrates predominant renal excretion at 80%. Rivaroxaban and edoxaban also undergo renal elimination, but to a lesser extent, at approximately 35% and 50%, respectively. [13]", "contents": "Apixaban -- Mechanism of Action -- Pharmacokinetics. Elimination: Apixaban undergoes elimination via both urine and feces and has an apparent half-life of 12 hours following oral administration. Among the DOACs, apixaban exhibits 27% renal elimination, and dabigatran demonstrates predominant renal excretion at 80%. Rivaroxaban and edoxaban also undergo renal elimination, but to a lesser extent, at approximately 35% and 50%, respectively. [13]"}
{"id": "article-35631_14", "title": "Apixaban -- Administration -- Available Dosage Forms and Strengths", "content": "Apixaban is available in the oral formulation as 2.5 mg and 5 mg tablets. Dosing depends on the indication for treatment, the patient's age, serum creatinine, and body weight.", "contents": "Apixaban -- Administration -- Available Dosage Forms and Strengths. Apixaban is available in the oral formulation as 2.5 mg and 5 mg tablets. Dosing depends on the indication for treatment, the patient's age, serum creatinine, and body weight."}
{"id": "article-35631_15", "title": "Apixaban -- Administration -- Adult Dosage", "content": "Patients with\u00a0DVT and PE\u00a0are required to take 10 mg twice daily for\u00a07 days, followed by 5 mg twice daily. In the European Union (EU) and by the FDA, apixaban currently holds approval as a prophylactic agent following hip and knee replacement surgeries. The recommended dosage for DVT prophylaxis post-hip or knee replacement surgery is 2.5 mg orally twice daily. It is advised to initiate the dosage 12 to 24 hours post-surgery, with a treatment duration of 12 days for knee replacement and approximately 35 days for hip replacement. [14] The recommended dosage for patients with nonvalvular atrial fibrillation is 5 mg twice daily. [13] However, for patients meeting at least 2 out of 3 criteria below, the dosage of apixaban 5 mg should be reduced to 2.5 mg daily. Age 80 or older Serum creatinine greater than or equal to 1.5 mg/dL Body weight less than or equal to 60 kg", "contents": "Apixaban -- Administration -- Adult Dosage. Patients with\u00a0DVT and PE\u00a0are required to take 10 mg twice daily for\u00a07 days, followed by 5 mg twice daily. In the European Union (EU) and by the FDA, apixaban currently holds approval as a prophylactic agent following hip and knee replacement surgeries. The recommended dosage for DVT prophylaxis post-hip or knee replacement surgery is 2.5 mg orally twice daily. It is advised to initiate the dosage 12 to 24 hours post-surgery, with a treatment duration of 12 days for knee replacement and approximately 35 days for hip replacement. [14] The recommended dosage for patients with nonvalvular atrial fibrillation is 5 mg twice daily. [13] However, for patients meeting at least 2 out of 3 criteria below, the dosage of apixaban 5 mg should be reduced to 2.5 mg daily. Age 80 or older Serum creatinine greater than or equal to 1.5 mg/dL Body weight less than or equal to 60 kg"}
{"id": "article-35631_16", "title": "Apixaban -- Administration", "content": "If the dosage is not scheduled, the patient should take the dosage as soon as possible within the same day and resume the twice-daily schedule. However, a double dose is not recommended to compensate for a missing dosage.", "contents": "Apixaban -- Administration. If the dosage is not scheduled, the patient should take the dosage as soon as possible within the same day and resume the twice-daily schedule. However, a double dose is not recommended to compensate for a missing dosage."}
{"id": "article-35631_17", "title": "Apixaban -- Administration", "content": "Other options for administration: The patients who have difficulty swallowing whole tablets may be able to crush and suspend 2.5 mg and 5 mg of apixaban tablets in water, apple juice, 5% dextrose in water (D5W), or applesauce and administer them orally immediately. These crushed tablets remain stable for up to 4 hours. Alternatively, these tablets may be crushed and suspended in 60 mL of water or D5W for prompt delivery via a nasogastric tube.", "contents": "Apixaban -- Administration. Other options for administration: The patients who have difficulty swallowing whole tablets may be able to crush and suspend 2.5 mg and 5 mg of apixaban tablets in water, apple juice, 5% dextrose in water (D5W), or applesauce and administer them orally immediately. These crushed tablets remain stable for up to 4 hours. Alternatively, these tablets may be crushed and suspended in 60 mL of water or D5W for prompt delivery via a nasogastric tube."}
{"id": "article-35631_18", "title": "Apixaban -- Administration -- Specific Patients Population", "content": "Hepatic impairment: The apixaban\u00a0dosage instructions for patients with hepatic impairment are listed below. Mild hepatic impairment (Child-Pugh class A): No dosage adjustment is required. Moderate hepatic impairment (Child-Pugh class B): Limited clinical experience in patients with moderate hepatic impairment; hence, any dosing adjustment has yet to be established. Severe hepatic impairment (Child-Pugh class C): Apixaban is not recommended. Renal impairment: As mentioned above, the recommended apixaban\u00a0dosage for patients with at least 2 of the following should be reduced from 5 mg to 2.5 mg twice daily. [14] Age 80 or older Serum creatinine greater than or equal to 1.5 mg/dL Body weight less than or equal to 60 kg", "contents": "Apixaban -- Administration -- Specific Patients Population. Hepatic impairment: The apixaban\u00a0dosage instructions for patients with hepatic impairment are listed below. Mild hepatic impairment (Child-Pugh class A): No dosage adjustment is required. Moderate hepatic impairment (Child-Pugh class B): Limited clinical experience in patients with moderate hepatic impairment; hence, any dosing adjustment has yet to be established. Severe hepatic impairment (Child-Pugh class C): Apixaban is not recommended. Renal impairment: As mentioned above, the recommended apixaban\u00a0dosage for patients with at least 2 of the following should be reduced from 5 mg to 2.5 mg twice daily. [14] Age 80 or older Serum creatinine greater than or equal to 1.5 mg/dL Body weight less than or equal to 60 kg"}
{"id": "article-35631_19", "title": "Apixaban -- Administration -- Specific Patients Population", "content": "A study examined apixaban dosing in atrial fibrillation with chronic kidney disease stage 4 or 5. Results demonstrated that 5 mg apixaban was associated with an increased bleeding risk than 2.5 mg dose. No clinically significant differences were apparent in the risk of stroke/systemic embolism or mortality between the 2 dosage groups. These findings support the dosing recommendations based on kidney function. The study underscores the imperative for further investigation in this area, emphasizing the necessity for tailored dosing strategies for patients with chronic kidney disease. [15] Clinical efficacy and safety studies with apixaban did not include patients with end-stage renal disease (ESRD) on dialysis. Therefore, it is not recommended on the drug label as a proven anticoagulant of choice in patients with ESRD. An alternate anticoagulant like warfarin should be considered in patients with ESRD.", "contents": "Apixaban -- Administration -- Specific Patients Population. A study examined apixaban dosing in atrial fibrillation with chronic kidney disease stage 4 or 5. Results demonstrated that 5 mg apixaban was associated with an increased bleeding risk than 2.5 mg dose. No clinically significant differences were apparent in the risk of stroke/systemic embolism or mortality between the 2 dosage groups. These findings support the dosing recommendations based on kidney function. The study underscores the imperative for further investigation in this area, emphasizing the necessity for tailored dosing strategies for patients with chronic kidney disease. [15] Clinical efficacy and safety studies with apixaban did not include patients with end-stage renal disease (ESRD) on dialysis. Therefore, it is not recommended on the drug label as a proven anticoagulant of choice in patients with ESRD. An alternate anticoagulant like warfarin should be considered in patients with ESRD."}
{"id": "article-35631_20", "title": "Apixaban -- Administration -- Specific Patients Population", "content": "Pregnancy considerations: A limited amount of data is available on the use of apixaban tablets in pregnant women and the associated risk of major congenital disabilities, adverse outcomes, or miscarriage. The treatment with the drug may lead to an increased risk of bleeding during pregnancy and delivery. As per the American College of Obstetricians and Gynecologists (ACOG), the use of dabigatran and anti-Xa Inhibitors (such as rivaroxaban, apixaban, and edoxaban) is not recommended during pregnancy due to the limited availability of safety data about the well-being of the mother, fetus, and breastfeeding neonate. Research involving human placental studies has indicated the passage of these inhibitors across the placenta, warranting caution regarding potential indirect effects on fetal blood coagulation. [16]", "contents": "Apixaban -- Administration -- Specific Patients Population. Pregnancy considerations: A limited amount of data is available on the use of apixaban tablets in pregnant women and the associated risk of major congenital disabilities, adverse outcomes, or miscarriage. The treatment with the drug may lead to an increased risk of bleeding during pregnancy and delivery. As per the American College of Obstetricians and Gynecologists (ACOG), the use of dabigatran and anti-Xa Inhibitors (such as rivaroxaban, apixaban, and edoxaban) is not recommended during pregnancy due to the limited availability of safety data about the well-being of the mother, fetus, and breastfeeding neonate. Research involving human placental studies has indicated the passage of these inhibitors across the placenta, warranting caution regarding potential indirect effects on fetal blood coagulation. [16]"}
{"id": "article-35631_21", "title": "Apixaban -- Administration -- Specific Patients Population", "content": "Breastfeeding considerations: Limited clinical data is available regarding apixaban or its metabolites in human milk. However, studies have shown that apixaban and its metabolites were detected in rat milk. The observed levels of apixaban in breast milk, ranging from 0.2 to 0.25 mg/L, correspond to a relative infant dose of 10% to 21% of the maternal weight-adjusted dosage. Given this significant transfer, it is advisable to consider alternative anticoagulants with lower excretion into breast milk, especially when nursing newborns or preterm infants. [17] Pediatric patients: The safety and efficacy of apixaban tablets have not been established in pediatric patients.", "contents": "Apixaban -- Administration -- Specific Patients Population. Breastfeeding considerations: Limited clinical data is available regarding apixaban or its metabolites in human milk. However, studies have shown that apixaban and its metabolites were detected in rat milk. The observed levels of apixaban in breast milk, ranging from 0.2 to 0.25 mg/L, correspond to a relative infant dose of 10% to 21% of the maternal weight-adjusted dosage. Given this significant transfer, it is advisable to consider alternative anticoagulants with lower excretion into breast milk, especially when nursing newborns or preterm infants. [17] Pediatric patients: The safety and efficacy of apixaban tablets have not been established in pediatric patients."}
{"id": "article-35631_22", "title": "Apixaban -- Administration -- Specific Patients Population", "content": "Older patients: No clinically significant difference is detected in the safety and efficacy of apixaban when comparing different age groups. The prior American Geriatrics Society (AGS) recommendation emphasized the importance of prudence when considering the use of apixaban in creatinine clearance (CrCl) below 25 mL/min. However, the 2023 AGS update now indicates that emerging evidence and clinical experience support its safe use at lower levels of renal function. [18]", "contents": "Apixaban -- Administration -- Specific Patients Population. Older patients: No clinically significant difference is detected in the safety and efficacy of apixaban when comparing different age groups. The prior American Geriatrics Society (AGS) recommendation emphasized the importance of prudence when considering the use of apixaban in creatinine clearance (CrCl) below 25 mL/min. However, the 2023 AGS update now indicates that emerging evidence and clinical experience support its safe use at lower levels of renal function. [18]"}
{"id": "article-35631_23", "title": "Apixaban -- Adverse Effects", "content": "As an anticoagulant, apixaban's most common adverse effect is bleeding (1% to 10%). The risk of major bleeding is 3% or less, and clinically relevant nonmajor bleeding is 2% to 4%. Other less common adverse effects include nausea (3%), gingival hemorrhage (1% or less), hematuria (2% or less), hypermenorrhea (1%), anemia (3%), bruise (1% to 2%), hematoma (1% to 2%), postprocedural hemorrhage (1% or less), rectal hemorrhage (1% or less), increased serum transaminases (1% or less), aspartate aminotransferase increased (1% or less), gamma-glutamyltransferase increased (1% or less), epistaxis (4% or less), and hemoptysis (1% or less). In rare instances (less than 1%), it can cause a hypersensitivity reaction. According to the FDA, apixaban is not recommended for patients with prosthetic heart valves. [19]", "contents": "Apixaban -- Adverse Effects. As an anticoagulant, apixaban's most common adverse effect is bleeding (1% to 10%). The risk of major bleeding is 3% or less, and clinically relevant nonmajor bleeding is 2% to 4%. Other less common adverse effects include nausea (3%), gingival hemorrhage (1% or less), hematuria (2% or less), hypermenorrhea (1%), anemia (3%), bruise (1% to 2%), hematoma (1% to 2%), postprocedural hemorrhage (1% or less), rectal hemorrhage (1% or less), increased serum transaminases (1% or less), aspartate aminotransferase increased (1% or less), gamma-glutamyltransferase increased (1% or less), epistaxis (4% or less), and hemoptysis (1% or less). In rare instances (less than 1%), it can cause a hypersensitivity reaction. According to the FDA, apixaban is not recommended for patients with prosthetic heart valves. [19]"}
{"id": "article-35631_24", "title": "Apixaban -- Adverse Effects -- Drug-Drug Interactions", "content": "Most apixaban drug interactions are associated with CYP3A4 and permeability glycoprotein (P-gp), as apixaban is a substrate for both. The drugs that inhibit CYP3A4 and P-gp may increase the exposure of apixaban and the associated risk of bleeding. On the contrary, drugs that induce CYP3A4 and P-gp may decrease exposure to apixaban and increase the risk of stroke and other thromboembolic events. [20] [21]", "contents": "Apixaban -- Adverse Effects -- Drug-Drug Interactions. Most apixaban drug interactions are associated with CYP3A4 and permeability glycoprotein (P-gp), as apixaban is a substrate for both. The drugs that inhibit CYP3A4 and P-gp may increase the exposure of apixaban and the associated risk of bleeding. On the contrary, drugs that induce CYP3A4 and P-gp may decrease exposure to apixaban and increase the risk of stroke and other thromboembolic events. [20] [21]"}
{"id": "article-35631_25", "title": "Apixaban -- Adverse Effects -- Drug-Drug Interactions", "content": "Coadministration of apixaban\u00a0and P-gp strong CYP3A4 inhibitors: Suppose patients receive apixaban 5 or 10 mg twice daily. In that case, it is recommended to decrease the dose of apixaban by 50% for patients who are also receiving P-gp and potent CYP3A4-inhibiting drugs such as ritonavir, ketoconazole, and itraconazole. However, if patients receive apixaban 2.5 mg twice daily, it is recommended to avoid coadministration for patients who also receive P-gp and potent CYP3A4 inhibitors.", "contents": "Apixaban -- Adverse Effects -- Drug-Drug Interactions. Coadministration of apixaban\u00a0and P-gp strong CYP3A4 inhibitors: Suppose patients receive apixaban 5 or 10 mg twice daily. In that case, it is recommended to decrease the dose of apixaban by 50% for patients who are also receiving P-gp and potent CYP3A4-inhibiting drugs such as ritonavir, ketoconazole, and itraconazole. However, if patients receive apixaban 2.5 mg twice daily, it is recommended to avoid coadministration for patients who also receive P-gp and potent CYP3A4 inhibitors."}
{"id": "article-35631_26", "title": "Apixaban -- Adverse Effects -- Drug-Drug Interactions", "content": "Coadministration of apixaban\u00a0and\u00a0P-gp strong CYP3A4 inducers: Coadministration of apixaban with other P-gp and strong CYP3A4-inducing drugs, such as phenytoin, carbamazepine, and rifampin, should be avoided, as these drugs may decrease the exposure to apixaban.", "contents": "Apixaban -- Adverse Effects -- Drug-Drug Interactions. Coadministration of apixaban\u00a0and\u00a0P-gp strong CYP3A4 inducers: Coadministration of apixaban with other P-gp and strong CYP3A4-inducing drugs, such as phenytoin, carbamazepine, and rifampin, should be avoided, as these drugs may decrease the exposure to apixaban."}
{"id": "article-35631_27", "title": "Apixaban -- Adverse Effects -- Drug-Drug Interactions", "content": "Coadministration of apixaban with other anticoagulants and antiplatelet agents: When apixaban is coadministered with other anticoagulants and antiplatelet agents, such as heparin, aspirin, and chronic nonsteroidal anti-inflammatory drugs (NSAIDs), it may increase the risk of bleeding.", "contents": "Apixaban -- Adverse Effects -- Drug-Drug Interactions. Coadministration of apixaban with other anticoagulants and antiplatelet agents: When apixaban is coadministered with other anticoagulants and antiplatelet agents, such as heparin, aspirin, and chronic nonsteroidal anti-inflammatory drugs (NSAIDs), it may increase the risk of bleeding."}
{"id": "article-35631_28", "title": "Apixaban -- Contraindications", "content": "Per the manufacturer's label, active pathological bleeding and severe hypersensitivity reaction to apixaban, for example, an anaphylactic reaction, are the contraindications to using apixaban. [22]", "contents": "Apixaban -- Contraindications. Per the manufacturer's label, active pathological bleeding and severe hypersensitivity reaction to apixaban, for example, an anaphylactic reaction, are the contraindications to using apixaban. [22]"}
{"id": "article-35631_29", "title": "Apixaban -- Contraindications -- Box Warnings", "content": "Thrombotic events: Premature discontinuation of oral anticoagulant medicines, including apixaban, can increase the risk of thrombotic adverse events. In cases where discontinuation of apixaban is necessary, it is advisable to provide alternative anticoagulant coverage.", "contents": "Apixaban -- Contraindications -- Box Warnings. Thrombotic events: Premature discontinuation of oral anticoagulant medicines, including apixaban, can increase the risk of thrombotic adverse events. In cases where discontinuation of apixaban is necessary, it is advisable to provide alternative anticoagulant coverage."}
{"id": "article-35631_30", "title": "Apixaban -- Contraindications -- Box Warnings", "content": "Spinal/epidural hematoma: Clinicians should monitor patients frequently for signs and symptoms of neurological impairment. Urgent treatment is necessary if neurological compromise is noted. When considering the utilization of apixaban, it is essential to evaluate potential interactions with other drugs that impact hemostasis, such as NSAIDs and alternative anticoagulants.", "contents": "Apixaban -- Contraindications -- Box Warnings. Spinal/epidural hematoma: Clinicians should monitor patients frequently for signs and symptoms of neurological impairment. Urgent treatment is necessary if neurological compromise is noted. When considering the utilization of apixaban, it is essential to evaluate potential interactions with other drugs that impact hemostasis, such as NSAIDs and alternative anticoagulants."}
{"id": "article-35631_31", "title": "Apixaban -- Contraindications -- Box Warnings", "content": "During neuraxial anesthesia or spinal puncture, careful scheduling and risk assessment are imperative due to the potential for hematomas. Therefore,\u00a0a thorough assessment of the patient's medical history is crucial, particularly focusing on any prior instances of traumatic or repeated epidural or spinal punctures. Furthermore, special attention should be given to individuals with a history of spinal deformity or previous spinal surgery. The optimal timing for administering apixaban\u00a0during neuraxial procedures remains uncertain.", "contents": "Apixaban -- Contraindications -- Box Warnings. During neuraxial anesthesia or spinal puncture, careful scheduling and risk assessment are imperative due to the potential for hematomas. Therefore,\u00a0a thorough assessment of the patient's medical history is crucial, particularly focusing on any prior instances of traumatic or repeated epidural or spinal punctures. Furthermore, special attention should be given to individuals with a history of spinal deformity or previous spinal surgery. The optimal timing for administering apixaban\u00a0during neuraxial procedures remains uncertain."}
{"id": "article-35631_32", "title": "Apixaban -- Contraindications -- Box Warnings", "content": "The American Society of Regional Anesthesia & Pain Medicine (ASRA) issues specific recommendations to mitigate the potential risk of spinal hematoma due to apixaban during pain procedures. ASRA advises a precautionary waiting period equivalent to 5 half-lives, or approximately\u00a03 days, between discontinuation of apixaban and medium- or high-risk pain procedures. For low-risk procedures, a collaborative assessment, risk stratification, and decision-making process involving the attending physicians should determine whether discontinuing apixaban is warranted. In such situations, a shorter interval of 2 half-lives may be considered. ASRA recommends a 24-hour interval after interventional pain procedures before resuming apixaban. In cases where the risk of VTE remains notably high, administering half the standard dose may be a viable option 12 hours after the pain intervention. [23]", "contents": "Apixaban -- Contraindications -- Box Warnings. The American Society of Regional Anesthesia & Pain Medicine (ASRA) issues specific recommendations to mitigate the potential risk of spinal hematoma due to apixaban during pain procedures. ASRA advises a precautionary waiting period equivalent to 5 half-lives, or approximately\u00a03 days, between discontinuation of apixaban and medium- or high-risk pain procedures. For low-risk procedures, a collaborative assessment, risk stratification, and decision-making process involving the attending physicians should determine whether discontinuing apixaban is warranted. In such situations, a shorter interval of 2 half-lives may be considered. ASRA recommends a 24-hour interval after interventional pain procedures before resuming apixaban. In cases where the risk of VTE remains notably high, administering half the standard dose may be a viable option 12 hours after the pain intervention. [23]"}
{"id": "article-35631_33", "title": "Apixaban -- Monitoring", "content": "Unlike warfarin, apixaban does not need monitoring of the patient's international normalized ratio (INR), offering an advantage. [24] Patients on warfarin must get their INR checked every week,\u00a02 weeks, or\u00a04 weeks, depending on the control, whereas patients using apixaban do not need any blood draws; this improves patient adherence. [25] [26]", "contents": "Apixaban -- Monitoring. Unlike warfarin, apixaban does not need monitoring of the patient's international normalized ratio (INR), offering an advantage. [24] Patients on warfarin must get their INR checked every week,\u00a02 weeks, or\u00a04 weeks, depending on the control, whereas patients using apixaban do not need any blood draws; this improves patient adherence. [25] [26]"}
{"id": "article-35631_34", "title": "Apixaban -- Monitoring", "content": "The most significant adverse effect is bleeding. Therefore, concomitant use of drugs affecting hemostasis, including antiplatelets, other anticoagulants, thrombolytic agents, NSAIDs, selective serotonin reuptake inhibitors (SSRIs), and serotonin and norepinephrine reuptake inhibitors (SNRIs), should be reasonable. The elimination half-life is about 12 hours (8 to 15 hours). Before a patient undergoes elective surgery or an invasive procedure, the drug should be held for 48 hours if the procedure is a moderate-high risk with clinically significant bleeding. For procedures with a low risk of bleeding, it should be held 24 hours before the procedure. Bridging anticoagulation 24 to 48 hours after is not usually recommended. [27] Furthermore, the drug must be restarted following surgical or other procedures after establishing adequate hemostasis.", "contents": "Apixaban -- Monitoring. The most significant adverse effect is bleeding. Therefore, concomitant use of drugs affecting hemostasis, including antiplatelets, other anticoagulants, thrombolytic agents, NSAIDs, selective serotonin reuptake inhibitors (SSRIs), and serotonin and norepinephrine reuptake inhibitors (SNRIs), should be reasonable. The elimination half-life is about 12 hours (8 to 15 hours). Before a patient undergoes elective surgery or an invasive procedure, the drug should be held for 48 hours if the procedure is a moderate-high risk with clinically significant bleeding. For procedures with a low risk of bleeding, it should be held 24 hours before the procedure. Bridging anticoagulation 24 to 48 hours after is not usually recommended. [27] Furthermore, the drug must be restarted following surgical or other procedures after establishing adequate hemostasis."}
{"id": "article-35631_35", "title": "Apixaban -- Toxicity", "content": "In May 2018, the FDA approved the first antidote for reversing factor Xa inhibitors called andexanet alfa. Andexanet alfa is a biological agent\u2014a modified recombinant derivative of factor Xa that acts as a decoy receptor. It has a higher affinity for factor Xa inhibitor than natural Xa; consequently, the inhibitor binds to the drug rather than to natural Xa itself. It received the US Orphan Drug and FDA Breakthrough Therapy designations. Due to its recent approval, limited real-world data is available on the use of this antidote. Further research will determine its efficacy and safety profile in the future. [28]", "contents": "Apixaban -- Toxicity. In May 2018, the FDA approved the first antidote for reversing factor Xa inhibitors called andexanet alfa. Andexanet alfa is a biological agent\u2014a modified recombinant derivative of factor Xa that acts as a decoy receptor. It has a higher affinity for factor Xa inhibitor than natural Xa; consequently, the inhibitor binds to the drug rather than to natural Xa itself. It received the US Orphan Drug and FDA Breakthrough Therapy designations. Due to its recent approval, limited real-world data is available on the use of this antidote. Further research will determine its efficacy and safety profile in the future. [28]"}
{"id": "article-35631_36", "title": "Apixaban -- Toxicity", "content": "Prothrombin complex concentrates (PCCs) are a mixture of factors II, IX, and X. Some PCCs include factor VII. Since the 1960s, it has been known to reverse laboratory measures and bleeding from factor Xa inhibitors such as rivaroxaban, apixaban, and edoxaban in healthy volunteers, animal models, and in vitro studies of healthy donor blood. One institution instituted a protocol of administering 4-factor PCC for patients with rivaroxaban-associated or apixaban-associated bleeding requiring immediate reversal. However, whether this strategy results in clinical improvements for such patients has yet to be determined. [28]", "contents": "Apixaban -- Toxicity. Prothrombin complex concentrates (PCCs) are a mixture of factors II, IX, and X. Some PCCs include factor VII. Since the 1960s, it has been known to reverse laboratory measures and bleeding from factor Xa inhibitors such as rivaroxaban, apixaban, and edoxaban in healthy volunteers, animal models, and in vitro studies of healthy donor blood. One institution instituted a protocol of administering 4-factor PCC for patients with rivaroxaban-associated or apixaban-associated bleeding requiring immediate reversal. However, whether this strategy results in clinical improvements for such patients has yet to be determined. [28]"}
{"id": "article-35631_37", "title": "Apixaban -- Toxicity", "content": "Ciraparantag, an investigational therapy, demonstrates a dose-dependent reversal of anticoagulation from steady-state apixaban or rivaroxaban treatment. However, it is important to emphasize that ciraparantag is not yet FDA-approved, stressing the necessity for further research and evaluation, particularly in toxicity. [29]", "contents": "Apixaban -- Toxicity. Ciraparantag, an investigational therapy, demonstrates a dose-dependent reversal of anticoagulation from steady-state apixaban or rivaroxaban treatment. However, it is important to emphasize that ciraparantag is not yet FDA-approved, stressing the necessity for further research and evaluation, particularly in toxicity. [29]"}
{"id": "article-35631_38", "title": "Apixaban -- Enhancing Healthcare Team Outcomes", "content": "All interprofessional healthcare team members, including clinicians, specialists (cardiologists, internists, hospitalists, hematologists, and others), nursing staff, and pharmacists who treat patients with atrial fibrillation should be well informed regarding pharmacotherapy with apixaban. The FDA approved this NOAC\u00a0for use in patients with nonvalvular atrial fibrillation to reduce the risk of stroke and blood clots, and it was later\u00a0approved to treat DVT and PE. In 2014, the drug was also FDA-approved to reduce the risk of blood clots (DVT and PE) in patients following knee and hip replacement surgery. [30] A study examined the role of pharmacists within the interprofessional healthcare team.\u00a0Implementing a pharmacist-driven DOAC protocol (pre-intervention and post-intervention) reduced the percentage of inappropriately administered DOACs, including apixaban, highlighting the vital contribution of pharmacists in optimizing anticoagulant therapy and preventing potential adverse events. [31]", "contents": "Apixaban -- Enhancing Healthcare Team Outcomes. All interprofessional healthcare team members, including clinicians, specialists (cardiologists, internists, hospitalists, hematologists, and others), nursing staff, and pharmacists who treat patients with atrial fibrillation should be well informed regarding pharmacotherapy with apixaban. The FDA approved this NOAC\u00a0for use in patients with nonvalvular atrial fibrillation to reduce the risk of stroke and blood clots, and it was later\u00a0approved to treat DVT and PE. In 2014, the drug was also FDA-approved to reduce the risk of blood clots (DVT and PE) in patients following knee and hip replacement surgery. [30] A study examined the role of pharmacists within the interprofessional healthcare team.\u00a0Implementing a pharmacist-driven DOAC protocol (pre-intervention and post-intervention) reduced the percentage of inappropriately administered DOACs, including apixaban, highlighting the vital contribution of pharmacists in optimizing anticoagulant therapy and preventing potential adverse events. [31]"}
{"id": "article-35631_39", "title": "Apixaban -- Enhancing Healthcare Team Outcomes", "content": "Unlike warfarin, the drug is relatively safe and does not need INR monitoring. However, ongoing close monitoring of patients taking apixaban is necessary to prevent bleeding; to this end, all clinicians, nurses, and pharmacists should counsel the patient so they are aware of the early signs of potential bleeding that could lead to more severe events.\u00a0If an overdose occurs, immediate action is necessary, including consultation with a hematologist. A critical care physician should supervise appropriate medical management in the medical intensive care unit. If any healthcare team member detects signs of bleeding, it is imperative to promptly communicate this to the prescriber to facilitate timely therapeutic intervention. Collaboratively, the interprofessional team must operate as a cohesive unit to ensure the safety and efficacy of apixaban treatment for their patients, ultimately aiming for optimal patient outcomes while minimizing adverse events.", "contents": "Apixaban -- Enhancing Healthcare Team Outcomes. Unlike warfarin, the drug is relatively safe and does not need INR monitoring. However, ongoing close monitoring of patients taking apixaban is necessary to prevent bleeding; to this end, all clinicians, nurses, and pharmacists should counsel the patient so they are aware of the early signs of potential bleeding that could lead to more severe events.\u00a0If an overdose occurs, immediate action is necessary, including consultation with a hematologist. A critical care physician should supervise appropriate medical management in the medical intensive care unit. If any healthcare team member detects signs of bleeding, it is imperative to promptly communicate this to the prescriber to facilitate timely therapeutic intervention. Collaboratively, the interprofessional team must operate as a cohesive unit to ensure the safety and efficacy of apixaban treatment for their patients, ultimately aiming for optimal patient outcomes while minimizing adverse events."}
{"id": "article-35631_40", "title": "Apixaban -- Review Questions", "content": "Access free multiple choice questions on this topic. Comment on this article.", "contents": "Apixaban -- Review Questions. Access free multiple choice questions on this topic. Comment on this article."}